Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) announced its fourth quarter and fiscal year 2020 results, highlighting key operational achievements and financial metrics. The company completed a public offering raising $69.0 million in January 2021, strengthening its balance sheet. Lantern's cash and equivalents stood at $19.2 million at year-end. R&D and G&A expenses increased significantly due to expansions in research activities and public company expenses. Notably, net losses were $2.9 million for Q4 2020, up from $0.7 million in Q4 2019. The company anticipates a transformational 2021 with advancements in drug trials and collaborations.
Lantern Pharma (NASDAQ: LTRN) will host a conference call on March 10, 2021, at 4:00 p.m. ET to discuss its fourth quarter and fiscal year 2020 results. The conference will be led by Panna Sharma, CEO, along with the management team. Participants can join via phone or online at their official webcast link. A replay will be available until April 10, 2021. Lantern Pharma utilizes its RADR® A.I. platform for drug discovery and aims to enhance patient outcomes through precision therapeutics, focusing on unmet clinical needs in oncology.
Lantern Pharma (LTRN) has successfully closed a public offering of 4,928,571 shares at $14.00 each, raising gross proceeds of approximately $69 million. The offering included 642,856 shares from the underwriter's over-allotment option. This follows the effective registration statement filed on January 14, 2021. Lantern focuses on transforming cancer drug development through its proprietary RADR® AI platform, targeting precision therapeutics for oncology. The funds raised may support the advancement of its clinical pipeline addressing unmet patient needs.
Lantern Pharma (LTRN) has announced a public offering of 4,285,715 shares at $14.00 per share, aiming for gross proceeds of $60 million, set to close on January 20, 2021. The underwriters hold a 45-day option to purchase an additional 642,856 shares to cover over-allotments. The offering is managed by ThinkEquity and Colliers Securities. A registration statement was filed with the SEC and is effective as of January 14, 2021. Lantern Pharma focuses on repurposing cancer therapies using AI and has two clinical-stage and one preclinical drug in its pipeline.
Lantern Pharma (LTRN) has announced the initiation of an Antibody Drug Conjugate (ADC) program, collaborating with Califia Pharma for development and evaluation. This program aims to target solid tumors and blood cancers using innovative linker technologies and DNA damage compounds, LP-100 and LP-184. Industry analysts project the global ADC market could exceed $10 billion by 2026. Lantern will leverage its RADR® A.I. platform to identify optimal cancer types and biomarker signatures for targeted therapies, intending to launch clinical trials by 2022.
Lantern Pharma (LTRN) announced a collaboration with Johns Hopkins to advance its LP-184 drug candidate for glioblastoma multiforme (GBM). This partnership aims to develop targeted applications for LP-184, utilizing patient-derived cancer models to enhance the understanding of its mechanisms. CEO Panna Sharma emphasized the significance of this collaboration in harnessing advanced methodologies and expanding the RADR® A.I. platform's data capabilities. The initiative seeks to improve patient outcomes in GBM, which has a grim five-year survival rate of only 5.5%.
Lantern Pharma (LTRN) announced promising preclinical data showing that its drug candidate, LP-184, can effectively cross the blood-brain barrier, crucial for treating Glioblastoma Multiforme (GBM). GBM, the most aggressive brain cancer, has a median survival of only 15 months and no current cure. The global GBM market is expected to reach $3.3 billion by 2024. Unlike standard treatments, LP-184 has a different mechanism of action, making it a potential option for patients resistant to current therapies. Lantern aims to accelerate clinical trials for LP-184, targeting a broader spectrum of CNS cancers.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO, Panna Sharma, will participate in three virtual investor events this December. Notable events include the Diamond Equity Research Emerging Growth Invitational on December 1, 2020, and the Benzinga Global Small Cap Conference on December 9, 2020. Lantern Pharma utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on drug repurposing and improving patient outcomes by identifying suitable candidates based on genomic profiles.
Lantern Pharma Inc. (NASDAQ: LTRN) reported financial results for Q3 2020, highlighting significant advancements in oncology drug development and its proprietary AI platform, RADR®. The company has three compounds in development: LP-100 in Phase 2 for metastatic prostate cancer, LP-300 preparing for Phase 2 for non-small cell lung cancer, and LP-184 in preclinical stages for various cancers. Notably, RADR® surpassed one billion data points, enhancing the drug development process. Cash and equivalents stood at $20.8 million, marking a substantial rise from $1.2 million at 2019's end, while net losses increased to $1.7 million.
Lantern Pharma (LTRN) will host a conference call on October 29, 2020, at 4:00 p.m. ET to discuss its financial and operating results for the third quarter ending September 30, 2020. The call, led by CEO Panna Sharma, will be accessible via teleconference and online, with a replay available until November 29, 2020. Lantern Pharma focuses on drug discovery and development in oncology, utilizing its RADR® artificial intelligence platform to optimize therapeutic outcomes for patients.